Table 1

Clinical characteristics, therapies and the number of patients who needed intensive care unit and mechanical ventilation in patients with and without COVID-19 atypical lymphocytes (COVID-19 LY) circulating in peripheral blood (n=36)

Patients with COVID-19 LY n=18Patients without COVID-19 LY
n=18
Age (years)53 (30–88)74 (46–90)
SexMen13 (72%)11 (61%)
Women5 (28%)7 (39%)
SymptomsFever18 (100%)16 (89%)
Cough13 (72%)14 (78%)
Dyspnoea10 (56%)9 (50%)
Nausea0 (0%)2 (11%)
Vomiting0 (0%)2 (11%)
Diarrhoea1 (6%)1 (6%)
Myalgia3 (17%)2 (11%)
Dysgeusia4 (22%)0 (0%)
Anosmia4 (22%)0 (0%)
Death0 (0%)4 (22%)
DrugsAntibiotic therapy17 (94%)18 (100%)
Antiviral therapy16 (89%)16 (89%)
Antiparasitic therapy17 (94%)17 (94%)
Antifungal therapy0 (0%)1 (6%)
ImmunosuppressionTocilizumab3 (17%)7 (39%)
Tocilizumab+Anakinra2 (11%)2 (11%)
Tocilizumab+Dexamethasone1 (5%)
Siltuximab1 (5%)
Anakinra1 (5%)
Intensive care unitYes1 (6%)9 (50%)
No17 (94%)9 (50%)
Mechanical ventilationYes1 (6%)8 (44%)
No17 (94%)10 (56%)